SEP 24, 2021 7:40 AM PDT

WHO Recommends Antibody Treatment for High Risk COVID-19 Patients

WRITTEN BY: Annie Lennon

The World Health Organization (WHO) has recommended a combination of two antibody treatments for patients at risk of adverse outcomes from COVID-19 infection. The corresponding guidelines with details of the underlying research were published in BMJ Medicine

With the fast pace of COVID-19 research, clinicians must have access to vetted and peer-reviewed research as it becomes available so they can best manage patients. The WHO's recommendations are a part of a living guideline to provide up-to-date and trustworthy guidance to doctors. The current guidelines supersede previous recommendations made on 6 July 2021. 

The drugs recommended by the WHO are called casirivimab and imdevimab. Both are monoclonal antibodies that, when used together, bind to the SARS-CoV-2 spike protein and prevent it from infecting cells where it can then multiply. 

From three trials that are yet to be peer-reviewed, the drugs appear to reduce the risk of hospitalization and duration of symptoms in those at the highest risk of severe disease. This includes people who are unvaccinated, older, or have weaker immune systems. 

Data from the RECOVERY trials also show that the drug combo may be able to reduce the chance of death among patients who are critically and severely ill with COVID-19, as well as their need for mechanical ventilation. These benefits, however, only appear significant for those who are seronegative- those who have not yet developed an antibody response to the virus. 

While the WHO recommends the combo treatment for now, they note that it is subject to change as new variants emerge. They also note that the treatment may be of limited use in low and middle-income countries due to cost and resource implications of rapid serological tests to identify patients, and staff and equipment to deliver and monitor intravenous drug delivery and allergic reactions. 

 

Sources: BMJ MedicineEurekAlert

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
NOV 29, 2022
Cell & Molecular Biology
How a Master Regulator May be Working to Protect Cancer
How a Master Regulator May be Working to Protect Cancer
Scientists have now discovered yet another way that MYC proteins can promote cancer. MYC has been called a master regula ...
JAN 05, 2023
Cannabis Sciences
The New Medical Marijuana and Cannabidiol Research Expansion Act
The New Medical Marijuana and Cannabidiol Research Expansion Act
New legislation is going to open up opportunities to research cannabis and its potential health benefits. Here are the d ...
JAN 19, 2023
Immunology
Surprising Finding Opens Up Novel Treatment Avenues for Lupus
Surprising Finding Opens Up Novel Treatment Avenues for Lupus
Lupus is an autoimmune disease that causes pain, inflammation and tissue damage. It can affect the brain, skin, joints, ...
JAN 19, 2023
Drug Discovery & Development
Newest Treatment for Rosacea: Encapsulated Benzoyl Peroxide Cream
Newest Treatment for Rosacea: Encapsulated Benzoyl Peroxide Cream
Rosacea is a dermatologic condition affecting the centrofacial region (cheeks, chin, nose, and forehead), resulting ...
JAN 22, 2023
Neuroscience
Research Study Explores the Mysterious Causes of Pediatric Epilepsy
Research Study Explores the Mysterious Causes of Pediatric Epilepsy
Childhood epilepsy affects roughly 4% of the pediatric population, and there are many different types of epilepsy and se ...
FEB 01, 2023
Cannabis Sciences
American and Canadian Cannabis Advertising Regulations Show Lack of Consistency in the US
American and Canadian Cannabis Advertising Regulations Show Lack of Consistency in the US
A University at Buffalo study that compared cannabis marketing policies in Canada and in various U.S. states found signi ...
Loading Comments...